LCAR-G08 is under clinical development by Legend Biotech and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LCAR-G08’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene-modified cell therapy is under development for the treatment of metastatic colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, and small bowel cancer. The therapeutic candidate acts by targeting cells expressing guanylate cyclase C (GCC). It is administered through parenteral route.
Legend Biotech overview
Legend Biotech, a subsidiary of Genscript Biotech Corp, is a clinical-stage biopharmaceutical company that discover and develops novel cell therapies for oncology and other indications. The company lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). The company utilizes CAR-T (chimeric antigen receptor-T cell), TCR (T-cell receptor) and allogeneic cell therapy technology platforms to develop its products. The company operates in the Americas and Europe. Legend Biotech is headquartered in Piscataway, New Jersey, the US.
For a complete picture of LCAR-G08’s drug-specific PTSR and LoA scores, buy the report here.